newsfilter
← Latest News
GlobeNewswire·

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

Phase 1a results support further development of TX000045 ("TX45") for Group 2 Pulmonary Hypertension in HFpEF ("PH-HFpEF"), based on favorable pharmacokinetic profile and impact on renal plasma flow ("RPF")TX45 showed a